Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 13/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL6496099 | 0.94 | HTR2C (0.42) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL6505719 | 0.83 | HTR2C (0.40) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL6495124 | 0.82 | KDM4E (0.41) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL6507609 | 0.82 | HTR6 (0.41) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL6508145 | 0.82 | HTR2C (0.51) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL6495595 | 0.81 | KDM4E (0.52) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL6502851 | 0.81 | HTR2A (0.34) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL7038313 | 0.80 | HTR2C (0.38) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Oxalic Acid SCHEMBL6496999 | 0.78 | HTR6 (0.38) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL6485011 | 0.76 | PTGDR2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | PFIZER | 2005-12-22 | — | — | US | claimed |
| EP-1173440-B1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | claimed |
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | PHARMACIA & UPJOHN COMPANY | 2002-12-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | TBXA2R, NPY5R, AZI2 | HTR2C 22/4885HTR2A 34/4885KDM4E 1036/4885 |
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | TPH1, AZI2, CYP1A2 | HTR2C 24/4885HTR2A 43/4885KDM4E 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.